Levena Biopharma, a US-based ADC specialty services company, was founded in 2013 upon licensing of proprietary, site-specific conjugation chemistries (C-Lock and K-Lock) from Concortis Biosystems (a Sorrento Tx company). Complemented by a growing portfolio of proprietary and non-proprietary Linkers and Payloads, we offer fully integrated CRDMO capabilities, world-class technical expertise and state-of-the-art lab facilities at our headquarters in San Diego, CA.

For clients seeking to construct therapeutic or diagnostic conjugates utilizing antigen-targeting biomolecule(s) of their choosing, we welcome discussing our IP and expertise to assist you. Levena was spun off from Sorrento in 2016 to independently serve the biopharma community. Since then, our collaborative partnerships have resulted in 28 successful IND registration packages.

Levena also offers leading-edge cGMP ADC manufacturing at our facilities in Nanjing (Ph1, 2) and Suzhou (Ph3+, >200g, Safebridge 6).